RYONCIL (remestemcel-L-rknd)
STEM CELL THERAPY · GRAFT-VERSUS-HOST DISEASE
MESOBLAST
Drug class
Stem Cell Therapy
Stem cell therapy represents a broad category of advanced cellular biologics rather than a single conventional pharmacological drug class. Read more about Stem Cell Therapy
1 drugs in this class 1 manufacturers
Drugs in Stem Cell Therapy
Filter & compare in the drug finder →
Opens the drug finder with Stem Cell Therapy preselected. Add indication or manufacturer filters there.
Stem cell therapy represents a broad category of advanced cellular biologics rather than a single conventional pharmacological drug class.
These therapies utilize living autologous or allogeneic progenitor cells that engraft, differentiate, self-renew, or secrete trophic factors to repair, regenerate, or replace damaged tissues and cells.
Regulatory-approved applications primarily center on hematopoietic progenitor cells used to reconstitute bone marrow and immune function following myeloablative therapy for hematologic malignancies and non-malignant blood or immune disorders.
Additional regulated applications, such as mesenchymal stromal cells, function via immunomodulation to manage severe complications like acute graft-versus-host disease.
-
fda.gov
Stem cell therapy represents a broad category of advanced cellular biologics rather than a single conventional pharmacological drug class These therapies utilize living autologous or allogeneic progenitor cells that engraft, differentiate, self-renew, or secrete trophic factors to repair, regenerate, or replace damaged tissues and cells
-
nih.gov
Stem cell therapy represents a broad category of advanced cellular biologics rather than a single conventional pharmacological drug class
-
fda.gov
These therapies utilize living autologous or allogeneic progenitor cells that engraft, differentiate, self-renew, or secrete trophic factors to repair, regenerate, or replace damaged tissues and cells Regulatory-approved applications primarily center on hematopoietic progenitor cells used to reconstitute bone marrow and immune function following myeloablative therapy for hematologic malignancies and non-malignant blood or immune disorders
-
fda.gov
These therapies utilize living autologous or allogeneic progenitor cells that engraft, differentiate, self-renew, or secrete trophic factors to repair, regenerate, or replace damaged tissues and cells Additional regulated applications, such as mesenchymal stromal cells, function via immunomodulation to manage severe complications like acute graft-versus-host disease
-
fda.gov
Regulatory-approved applications primarily center on hematopoietic progenitor cells used to reconstitute bone marrow and immune function following myeloablative therapy for hematologic malignancies and non-malignant blood or immune disorders
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.